Hypervascular Tumors clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Obsidio™ Conformable Embolic Registry
Sorry, not currently recruiting here
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
at UCLA
Our lead scientists for Hypervascular Tumors research studies include Siddarth Padia, MD.